Terms: = Endocrine gland cancer AND CBLB, DKFZp686J10223, 868, ENSG00000114423, Nbla00127, RNF56, FLJ41152, FLJ36865, DKFZp779F1443, DKFZp779A0729 AND Staging
5 results:
1. Five-Year Outcomes of FOLFIRINOX vs Gemcitabine as Adjuvant Therapy for Pancreatic cancer: A Randomized Clinical Trial.
Conroy T; Castan F; Lopez A; Turpin A; Ben Abdelghani M; Wei AC; Mitry E; Biagi JJ; Evesque L; Artru P; Lecomte T; Assenat E; Bauguion L; Ychou M; Bouché O; Monard L; Lambert A; Hammel P;
JAMA Oncol; 2022 Nov; 8(11):1571-1578. PubMed ID: 36048453
[TBL] [Abstract] [Full Text] [Related]
2. Magnetic Resonance Imaging Radiomics-Based Nomogram From Primary Tumor for Pretreatment Prediction of Peripancreatic Lymph Node Metastasis in Pancreatic Ductal Adenocarcinoma: A Multicenter Study.
Shi Z; Ma C; Huang X; Cao D
J Magn Reson Imaging; 2022 Mar; 55(3):823-839. PubMed ID: 34997795
[TBL] [Abstract] [Full Text] [Related]
3. Establishment and validation of a nomogram model for predicting the survival probability of differentiated thyroid carcinoma patients: a comparison with the eighth edition AJCC cancer staging system.
Zhang R; Xu M; Liu X; Wang M; Jia Q; Wang S; Zheng X; He X; Huang C; Fan Y; Wu H; Xu K; Li D; Meng Z
Endocrine; 2021 Oct; 74(1):108-119. PubMed ID: 33822318
[TBL] [Abstract] [Full Text] [Related]
4. MiR-34a-5p directly targeting TRIM44 affects the biological behavior of ovarian cancer cells.
Li HL; Duan YA; Zhao N
Eur Rev Med Pharmacol Sci; 2021 Feb; 25(3):1250-1260. PubMed ID: 33629295
[TBL] [Abstract] [Full Text] [Related]
5. Histopathologic features of ovarian borderline tumors are not predictive of clinical outcome.
Avril S; Hahn E; Specht K; Hauptmann S; Höss C; Kiechle M; Höfler H; Schmalfeldt B
Gynecol Oncol; 2012 Dec; 127(3):516-24. PubMed ID: 23000388
[TBL] [Abstract] [Full Text] [Related]
